Stable gastric pentadecapeptide BPC 157-NO-system relation
Sikiric et al./PubMed/2015
Why It Matters
This paper caught my attention because BPC-157 is increasingly popular in biohacking circles, but the evidence is entirely preclinical. While the animal data spans multiple organ systems (cardiovascular, GI, wound healing), there's zero human trial data presented here. The NO-system interaction is interesting mechanistically, but we're still guessing at human relevance. Not a doctor. Just a guy who reads the papers.
Key Findings
- BPC-157 competed with both L-NAME (NO-blocker) and L-arginine (NO-precursor) in animal models, suggesting it can modulate nitric oxide production bidirectionally depending on context
- Reduced thrombosis in abdominal aorta anastomosis models while simultaneously reducing bleeding in amputation and anticoagulant models — suggesting tissue-context dependent effects
- Showed protective effects across diverse injury types in animals: gastric alcohol lesions, chronic heart failure, pulmonary hypertension, electrolyte disturbances, and fistula healing
- Stimulated egr-1 and naB2 gene expression and affected eNOS gene expression, providing potential mechanisms for wound healing effects
- No lethal dose (LD1) was achieved in safety testing, indicating low acute toxicity in animals tested
Read the Paper↗PMID: 23755725